Furthermore, Ezrin small molecule inhibitors like NSC 305787 and NSC 668394, initially employed in osteosarcoma treatment (Bulut et al., 2012), hold potential for PCa therapy by hindering Ezrin phosphorylation and its interaction with actin. This evidence concerns the gene EZR and osteosarcoma.